Rhine R. Shen

Second Military Medical University — China

Medicine · Health Sciences

22h-index3.1kcitations144works4.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(63), Lymphoma Diagnosis and Treatment(30), Acute Myeloid Leukemia Research(22), NF-κB Signaling Pathways(18), Cancer Genomics and Diagnostics(14)

Publications144 total

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363
Blood·2025Open Access
Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL
Blood·2025Open Access
Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study
Blood·2025Open Access
Endogenous regulation of inflammatory response as a determinant of durable remission without stem cell transplant following brexucabtagene autoleucel (Brexu-cel) therapy in ALL
Blood·2025Open Access
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3
Blood·2025· 1 cited
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Journal of Clinical Oncology·2025· 4 citedOpen Access
Genomic correlates of clinical CAR-T cell activity
2025Open Access
Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data
Journal for ImmunoTherapy of Cancer·2025· 1 citedOpen Access
Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel (axi-cel) therapy in relapsed/refractory large B-cell lymphoma (LBCL).
Journal of Clinical Oncology·2025
A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Journal of Clinical Oncology·2025· 1 cited
Sepsis Important Genes Identification Through Biologically Informed Deep Learning and Transcriptomic Analysis
Clinical and Experimental Pharmacology and Physiology·2025· 1 cited
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survival
Experimental Hematology and Oncology·2025Open Access
Abstract 867: Multi-omic characterization of tumor microenvironment evolution in LBCL across treatment lines: Insights from Atlas classification and axicabtagene ciloleucel trials
Cancer Research·2025
Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
Frontiers in Oncology·2025· 2 citedOpen Access
Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma
Blood Advances·2025· 7 citedOpen Access
Rapid Increase in Blood CD19 CAR-T Vector Load during the First 5 Days Post Infusion Is Associated with Severe Icans
Transplantation and Cellular Therapy·2025
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Journal for ImmunoTherapy of Cancer·2025· 11 citedOpen Access
5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Blood·2024· 14 citedOpen Access
In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript
Blood·2024
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel
Blood·2024Open Access
page 1 of 8Next →

Frequent Co-authors

Caron A. Jacobson(18), Olalekan O. Oluwole(13), André Goy(11), John M. Timmerman(11), Frederick L. Locke(10), Brian T. Hill(10), Harry Miao(10), William C. Hahn(9), Sattva S. Neelapu(9), Simone Filosto(9), Saran Vardhanabhuti(9), Ian W. Flinn(8), Marie José Kersten(8), Javier Muñoz(7), Patrick M. Reagan(7), Michael A. Teitell(7), Sven de Vos(7), Adrian Bot(7), Peter A. McSweeney(6), David B. Miklos(6)